Are you looking for expert advice...

Since the legalisation of cannabis-based medicinal products (CBPMs) in the UK in November 2018, around 40,000 patients have received these treatments, with numbers steadily increasing. There are currently 40 clinics and about 140 prescribers operating within the private sector.

However, the adoption of these medicines within the NHS has been slow, and there are no compulsory training requirements for prescribers. This has led to significant variations in clinical practice.

To address these challenges, the Medical Cannabis Clinicians Society (MCCS) has developed a Good Practice Guide. This guide aims to support prescribers and ensure patients can safely access these valuable medicines. While it is tailored primarily for clinics that focus on prescribing cannabis, the fundamental principles are relevant to a broader range of medical settings.

The MCCS hopes this guide will be adopted widely, pleading to practices that benefit patients and improve the overall quality of the medical cannabis industry.  This effort highlights our dedication to raising standards and supporting prescribers with practical, applicable guidelines and support.

Download the Good Practice Guide >>>


You can access all our public publications – including this recently published Good Practice Guide – on our website.

Not yet a member? Join the Society.

The Medical Cannabis Clinicians Society (MCCS) and Volteface have been successfully elected as the new secretariat for the Medical Cannabis under Prescription APPG – bringing new bold strategy and commitment to working collaboratively with parliament, the industry and patients to improve the UK landscape.

Since legalisation of medical cannabis in 2018 a number of significant barriers have formed – from a lack of awareness to the continued struggle of paediatric access. The tireless work of MPs in the APPG to date to raise awareness of these issues in parliament has been challenging and at times been met with strong opposition from the government. The new focus of the APPG seeks to find allies both in and out of parliament who can provide evidence-based and practical solutions to overcoming the existing barriers.

These areas of focus include:

  1. Awareness amongst the British public that it is available on prescription
  2. Policy model in place is limiting and should explore broader prescribing (i.e. GPs)
  3. Number of prescribing clinicians and the hesitancies cannabis-naïve clinicians face
  4. Competition with the illicit market in regards to pricing, quality, distribution and cultivation
  5. Stigma among the British public, exploring how medical cannabis can appropriately fit into mainstream healthcare
  6. Highlighting the challenges of paediatric access. Families are faced with very high costs compared to adult patients and a lack of prescribers.

The new secretariat offers a vast amount of industry and medical cannabis expertise. Volteface and MCCS have an expansive network across politics, mainstream media, the clinical sphere, the cannabis industry, patients and advocacy groups.

Both organisations have a deep understanding of the sector and the issues facing it. With this expertise they are well positioned to help instigate adequate change.

The secretariat feels particularly strongly about collaborating with patient groups to ensure their needs are addressed and are a centre point for engaging Westminster on the issue. Alongside this, as professionals in the sector, Volteface and MCCS wants to ensure that the industry is positioned appropriately within parliament and has a voice to raise pertinent issues around the sustained development of the sector.

Tonia Antoniazzi, Labour MP and co-chair of the APPG for medical cannabis under prescription said: “As co-chair of the APPG I’m delighted to welcome Volteface and The Medical Cannabis Clinicians Society as the new secretariat of the group. Volteface and the MCCS have a wide range of expertise which will be extremely valuable moving forward.

Progress has been slow since the law change almost 5 years ago, so it is vital that we keep this conversation alive. I’m looking forward to working alongside our new secretariat in addressing the barriers to accessing medical cannabis under prescription and I hope we can start to see change happen.”

Leon Barron, Chair of the Medical Cannabis Clinicians Society said: “I am delighted that the MCCS along with Volteface have been appointed as secretariat to the APPG on medical cannabis. We look forward to moving this conversation forwards and to bridge the gap between policy makers, clinicians, and academics. Medical cannabis is being utilised widely across the globe and has proven efficacy for a range of chronic conditions. It can play a crucial role in relieving suffering and enhancing overall quality of life.  Our priority must be to find pragmatic solutions to the barriers that are restricting eligible patients in the UK accessing these medicines and we must ensure that all doctors, including GPs feel well informed and confident in prescribing medical cannabis.”

Hannah Deacon Executive Director of the Medical Cannabis Clinicians Society said: “It is an honour to be appointed secretariat to the APPG on medical cannabis. I am excited to be working with Volteface who have proven experience in this area and together I feel we will make an important contribution to ensuring the APPG continues to push forward to issues that patients, clinicians and the medical cannabis industry face. I know only too well of the suffering that patients continue to endure and the difficulties clinicians face in trying to access this prescribable medicine for their patients. I hope working together we can help move things forward to a place where patients and clinicians are better served and the industry is able to function in a more streamlined manner.”

Paul North, Director of Volteface said: “It is imperative that we work together to improve medical cannabis access and prescribing in the UK. The key to that collaboration is through parliament – an environment which can facilitate learning, find solutions to complex problems and lead to the formation of effective policy. Volteface has been engaging MPs and policy makers since its inception in 2017 and we are well aware of the challenges that lie ahead of us. Alongside our friends and colleagues at MCCS we are determined to provide MPs with the resources, knowledge and steer they need to improve medical cannabis prescribing in the UK.”

Katya Kowalski, Head of Operations of Volteface said: “I’m thrilled to be working with the APPG and the MCCS to advance the conversation around medical cannabis in parliament. Working in the sector it has been so frustrating to see the dialogue stagnate politically. There is still so much that needs to be done, particularly around effectively communicating the state of play to policy makers to raise awareness about the legality and accessibility of this medicine. There are a multitude of issues that need to be addressed for the sector to thrive and for patients to be tended to, and I look forward to advancing this through our role within the APPG.”


The Medical Cannabis Clinicians Society maintains a list of available cannabis-based medical products regularly updated and shared with its members.

As a member of the Medical Cannabis Clinicians Society, clinicians are supported with all the practical guidance they need prescribe medical cannabis safely, including training, education, peer and expert support and mentoring, FAQs and access to an accurate product list of available medications.

In the latest update for members, we have included new products available for the first time in the UK from Stenocare via Rokshaw and PCCA Ltd. Stenocare, founded in 2017, cultivates, produces, imports and sells prescription-based medical cannabis, focusing on Patient Safety, Affordability & Accessibility. In 2018, Stenocare became the first Danish company to obtain all permits to cultivate, import and trade in medicinal cannabis oils in the Danish pilot program. Stenocare is the only Danish company that has succeeded in having medical oil-based cannabis products approved for the Danish pilot program and supplies pharmaceutically-produced and uniform oil products to patients in Denmark, Sweden, Norway, UK and Australia.

All Stenocare medical cannabis sublingual oil products are produced in accordance with Good Agricultural and Collection Practices (GACP) without the use of pesticides and Good Manufacturing Practice (EU GMP) for Pharmaceutical Products. Stenocare’s products are whole-plant (full spectrum) cannabis-based medicines, that are tested for quality and compliance at external laboratories.

To access the product list, members can login here. Not yet a member?  Join the Medical Cannabis Clinicians Society.



John Ellis lives with Progressive Mylopathy of uncertain cause. Here, he tells his story.

A decade of declining health

In early 2002 whilst working as a broadband technician, I began to notice loss of memory and a change in smell and taste. After a few months of this problem worsening I was put-on long-term health support with the company, as my work required quick and accurate recall a lot of technical information.

After undergoing private cognitive therapy without much success in outcomes, I spent the next few years with my wife supporting our local community, creating a community group working with the police and other official bodies. In later years we set up a community garden with the help of other locals. It was during the latter years that my illness worsened and by 2010 cognitive loss, general pain and inability to mobilise myself properly had started to set in.

By 2011/2012 my condition had become progressively worse, to the point where I needed assistance to walk. I had already visited my doctor several times with different doctors viewing my deterioration in several ways. One even put all my issues down to my use of cannabis for pain management, even though I explained why I thought it worked better than non-steroidal anti-inflammatory drugs. Eventually, I engaged with a doctor that saw me as a patient first. He immediately arranged for an appointment with Walton Hospital and a neurologist.

Reaching a diagnosis

After undergoing a raft of physical tests including an MRI, my first initial diagnosis was for Primary Progressive Multiple Sclerosis. This was ruled out and changed to Progressive Myelopathy of uncertain cause.

The MRI showed lesions in the upper right pons – part of the brainstem – and many white matter lesions, whilst somatosensory test showed I had lost the somatosensory pathways back to my central cortex. This means the electrical signals travel out from my brain but do not travel back to the central cortex. The blood test results showed very low copper/Ceruloplasmin levels and lactic acid levels well above normal.

The symptoms of the copper deficiency are wide ranging, affecting everything from cellular respiration to enzyme production involved in neurological messenger breakdown, normally only seen in people who have had bariatric surgery presenting with a loss of gait and lower body functions and muscle spasms. Normally, replacing copper fixes the problem, but for me, the copper levels stayed low and fell even further over the years.

Chronic, long-term pain

I’m in almost constant pain. It is not what I would describe as normal pain – more of a sensory overload/emptiness, with smooth objects I hold feeling like they are made from a million tiny needles to hot wires being pulled through muscle and skin and numbness to the touch in my legs.

Exhaustion and fatigue are common problems with my illness, aggravated greatly with any form of exercise or rise/fall in external temperatures. Some days my body temperature can stay at 35.6 degrees and can stay that way for days. At my worst, a flare up can take a month or two to recover from.

I have trailed several prescription drugs over the years to help with pain management.

My pain specialist said that there is no mechanical intervention that can help – such as gabapentin and amitriptyline, both of which amplified the discomfort. Lamotrigine caused horrendous locked-in dreams and night terrors. I was taken off Lamotrigine after three weeks due to possible psychosis through lack of sleep, as I became terrified to sleep.

Since then I have partly stabilised on sodium valproate, baclofen, solifenacin succinate, copper supplement and currently 0.3 grams of cannabis at bedtime which I limit due to costs.

My medical cannabis journey

I have always been aware of cannabis, using it both recreationally when I was younger and now for medical use. I’m a very long way of gaining a prescription however, as the current costs are prohibitive to me. So, I rely on black market cannabis.

My Consultant and Pain Management Specialist have both been supportive on my medical notes have listed ‘up to a gram and a half per day’ under ‘current medication’, even though this is not via a prescription as it is unaffordable at those quantities and is not yet available on the NHS.

When I was first diagnosed, I was offered a month trial of Sativex. I turned this down as I had already enquired with my CCG about prescription costs – which they had already refused on costs alone. I was however lucky enough to try Sativex several years later during a visit to Parliament regarding the prescription of cannabis products.

Sativex turned out to be very effective for most of my symptoms, reducing my tiredness and fatigue as well as the pain and spasticity in my legs. I have done the majority of my own research over the years on how it effects my illness, even surprising some of my medical providers with knowledge on how cannabinoids interact with parts of my illnesses.

The future of medical cannabis prescriptions

I believe it is vital for everyone that cannabis prescriptions and cannabis-based products are brought onto the NHS, in part because of the unreliability of black market cannabis and more importantly the general health of patients.

Like many ordinary people, I don’t have the income to be treated via private clinics with a basic prescription and costs equating to nearly a third of our income per month.

All we are asking for is a replication of the Dutch Bedrocan range of plants and oils which will suit most patient’s needs.


John Ellis is a member of the Society’s Patient Committee.

Sue Evans from York uses medical cannabis treatment to alleviate chronic pain caused by cancer.  Here, she tells her story.

Sue Evans

In December 2015 I was diagnosed with breast cancer in my right breast. I underwent a lumpectomy and a 4 week intensive course of radiotherapy.  I refused chemotherapy because I considered it to be too invasive a treatment for me. In 2016 I did however, begin an endocrine treatment (Tamoxifen) to help prevent a resurgence of the cancer.

Sadly for me, one week into this endocrine treatment I suffered liver failure: I was told I had three years to live unless my liver repaired itself.  I stopped the endocrine treatment, cut out alcohol and started an alkaline diet. Thankfully my liver recovered within three months and still functions well, however I was left with a threat of an associated condition called Varices, a weakening of the veins which can cause internal bleeding. To date, my follow up breast scans continue to be clear, which is positive.

Turning to CBD for chronic, long-term pain 

In 2018, I developed pain in my right pelvic area which was later aggravated by a fall I had on an icy path. A bone density scan I had previously had in 2017 had revealed mild Osteopenia, so I attributed the pain in my pelvis to that condition and I did not consult a Doctor.

I did not want to rely on long term conventional painkillers for my hip because I was concerned they could aggravate the Varices threat which later down the line proved to be correct and also my liver, so I researched CBD oil as an alternative pain relief.  This was no easy feat, and an expensive one, as I discovered that many brands and strengths below 1000mg did not have any effect at all on my pain. However, after two months of trailing different types I did find a CBD full spectrum (no THC) 1200mg product that instantly relieved the pain, but I had to take frequent dosages to completely control it. But it did so effectively.

In November 2019 I fell ill with an unidentified infection which caused much pain in my lower left abdomen. Despite various tests, doctors were unable to diagnose the nature of the infection, which resulted in three different courses of antibiotics being prescribed, over a period of two months. I ceased CBD oil at this time as I didn’t know if it would interfere with the medication and therefore resorted to conventional pain killers to alleviate both the abdominal pain and the chronic pain in my right hip.  Sadly, the infection did not go away and after two months of this excessive pain I was rushed into hospital in January 2020, with severe internal bleeding in the stomach and upper digestive tract.

Secondary cancer diagnosis & prescription medical cannabis treatment 

The internal bleeding was treated successfully and the intravenous antibiotic I was given in hospital seemed to clear up the mystery infection. However, during my week of hospitalisation a scan of my abdomen revealed bony metastases (secondary breast cancer) in my right pelvis and lower spine. Unbeknown to me this had been the cause of the chronic pain in my right hip. So despite my breast scans remaining clear it appears the cancer had resurfaced in my spine and pelvic area.

Following a consultation with an Oncologist I agreed to take a different Endocrine treatment (Letrezole), to manage the cancer going forward. I also resumed the CBD oil for the pain relief. I am unable to take conventional pain killers due to the Varices, so I realised that if the cancer got worse I would potentially need a stronger CBD medication to control any increased pain, which is what prompted me to look for a private, qualified medical cannabis consultant.

A breast cancer nurse assisted me with this task and I was introduced to Dr Liz Iveson, a member of the Society’s expert committee. Since March 2020 I have been taking prescription Bedrolite CBD oil to manage the chronic pain in my pelvis. The medical CBD is stronger than the self-medicating CBD oil I had taken previously, so I require a much lesser dose to achieve the same level of pain control.

I now take the Letrozole endocrine treatment, which luckily I have not had an adverse reaction to, and the medical cannabis for the pain relief. My three monthly checks and blood tests show that the cancer is being effectively managed.

Successfully managing pain with prescription CBD

I personally have not experienced any side effects from either non medical or medical cannabis. Though I sleep much better at night as a result of CBD, it does not cause drowsiness during the day, so it does not affect my ability to drive safely. Also my ongoing blood tests and scans show that it is not interfering with the endocrine medication I take.

To sum up my experience with CBD oil, it allows me to enjoy a pain-free, full life rather than a painful existence. I very much enjoy walking as a means to relax; with CBD oil I can walk 6 or 7 miles easily with no problem at all. Without CBD oil I struggle to walk a mile and I limp quite profusely, even getting into a standing position is difficult.

CBD treatment makes a huge difference to the quality of my life, keeping a positive attitude does too. I refuse to dwell on how many years I will live with cancer. I do not want to waste my life thinking about the day I will die. I enjoy my life and intend to continue doing so.

As a last point I would like to counter argue the placebo effect that some label CBD with. In my early days of research I had to try various brands and strengths of CBD until I found one that worked. This was extremely time consuming and very costly. If, I had been of a placebo mindset, trust me I would have settled on the first brand I tried and saved myself a whole lot of time and money!

I can only sing the praises of medical cannabis from my personal experience, and would urge anyone suffering chronic pain to at least try it. You may be surprised at what a beneficial difference it can make to one’s quality of life and mental well being.

Thank you for reading my story.

Sue Evans is a member of the Society’s Patient Committee.


The Medical Cannabis Clinicians Society is an independent community of medical cannabis pioneers – the first prescribers of this treatment in the UK. We believe that every patient who could benefit from medical cannabis should have access to it.

Though we are primarily are a society for clinicians and health care professionals, we think it’s crucial that patient voices are heard. To ensure we remain an inclusive, relevant, informed, and open organisation, we’re launching a patient committee, made up of medical cannabis patients and patient advocates from across the UK.  This patient committee will take the lead on our work with independent patient groups from across the sector. 

Members of the MCCS Patient Committee will be required to attend a bi-monthly online meeting where we will discuss priorities for the Society, feedback on publications and projects and discuss relevant developments. Membership is limited to 10. To apply, please email [email protected] with a brief cover letter explaining why you would like to be involved.  The closing date is Wednesday 15 July 2020. 

PLEA (Patient Led Engagement for Access) has been established to challenge the inequalities in access to cannabis-based medicinal products in the UK.

Despite the 2018 schedule change allowing doctors to prescribe medicinal cannabis, patients are still faced with multiple barriers, including misinformation, stigma, and financial constraints, preventing access to potentially life-changing medicine.

PLEA’s mission is to advocate for quality of life with medicinal cannabis, aiming to enable patients to access their medicine free from the harms of stigmatisation, misinformation and financial barriers.

Patients are in need of assistance to navigate complex healthcare systems, clinicians wish to learn from patient experiences, and research is needed to evidence the efficacy and safety of medicinal cannabis. PLEA collaborates with patients, clinicians and researchers as one community, sharing knowledge and experiences in order to advance access to medical cannabis.

As with The Medical Cannabis Clinicians Society, PLEA is a non-profit, volunteer-run community interest company, enabling the team to advocate for patients free from commercial interference.

Working closely with Drug Science as a member of their Medical Cannabis Working Group, PLEA will support patients accessing Project Twenty21, Europe’s largest body of evidence for the safety and efficacy of prescribed medicinal cannabis.

Find out more about please visit


*March 2021 Update: Members of the Medical Cannabis Clinicians Society can now access exclusive medical cannabis insurance under our low-cost Group policy. Please read our updated information here.

At The Medical Cannabis Clinicians Society, we’re dedicated to providing straightforward guidance, information and support for clinicians wishing to prescribe medical cannabis.  Doctors often come to us with questions about their professional indemnity and insurance coverage, with some insurers not including medical cannabis treatments in their packages.

In England, doctors working for NHS trusts and health and social care bodies are provided with indemnity insurance through the Clinical Negligence Scheme for Trusts (CNST). Similar arrangements are in place for Scotland, Northern Ireland, and Wales.

Insurance for private practice

When it comes to being insured for prescribing medical cannabis, due to current prescribing restrictions, things are different. As medical cannabis in the UK is currently only available privately, doctors working outside of the NHS – often for the first time – have questions about how to arrange insurance and indemnity which covers this treatment.

The General Medical Council states that doctors working in private practice in the UK must have “adequate and appropriate insurance or indemnity arrangements in place covering the full scope of your medical practice”. This means that even if doctors are working privately within an NHS or health and social care body premises, they must still be covered.

Prof Michael Barnes, Chair of the Medical Cannabis Clinicians Society said, “Apart from two specific medications, Sativex and Epidiolex, medical cannabis – along with many other treatments – is at present classed as an unlicensed medicine. Doctors prescribing unlicensed products take full clinical responsibility for any consequences of the prescription and might not be covered by professional indemnity insurance. This is something that causes many clinicians concerns and prevents more widespread prescribing.

 Medical cannabis is a safe treatment with often significant benefits and few side effects. Clinicians can be reassured that if they prescribe within the legal parameters then they are very safe – although they still need insurance cover.”

Finding insurance that covers medical cannabis prescribing

When you are looking for new insurance, which includes medical cannabis, as a doctor operating in the private sector for the first time, or you’re renewing your existing coverage, it’s important to choose your provider well.

If doctors are already working privately, with insurance already in place, then it is important to check with your insurer that the changes in your scope of practice – i.e. starting to prescribe medical cannabis products – are included in your existing coverage.

Next steps

The route to becoming a medical cannabis prescriber in the UK can be a complex one, with regulations and rules to follow to ensure you are on the right side of the law. From being aware of the guidelines on medical cannabis to following the route for controlled drugs, read our guide ‘How to prescribe medical cannabis’, available here.

Read How to prescribe medical cannabis.

Hilary Latham from York uses medical cannabis treatment as part of her cancer treatment. Here, she tells her story.

In September 2009 I was diagnosed with breast cancer. One mastectomy later I was told the operation had been a success. I was one of the lucky ones… or so I thought.

Ten years later, in February, I moved to York to be near my two daughters, my new grandson, plus another grandchild on the way. Things were looking good. Aged 65, single (apart from the love of my life, my dog!), I was still fit enough to chase my grandchildren around the garden and continue my successful painting and decorating business.

As this year progressed I noticed that my mild asthma was getting progressively worse and by July I was feeling quite ill. A trip to the doctors was quickly followed up by admission to hospital where I was told the cancer was back and had spread to my liver. As a secondary cancer, I realised I wasn’t going to be so lucky this time. My oncologist confirmed I had stage 4 cancer and my life expectancy, without chemotherapy, was just a matter of months, and with successful chemotherapy I had perhaps one to two years.

Considering chemotherapy treatment

I had always thought that if the cancer returned, I wouldn’t have chemotherapy, I didn’t want to spend whatever time I had remaining in this life to be spent on an endless merry go round of potentially debilitating treatment. I also hadn’t planned on the additional complication of hypercalcemia. The cancer was affecting the amount of calcium in my blood, which can be life-threatening. I was very poorly.

As an active outdoorsy type of person, quality of life is so important to me. I realized that the prognosis of just a few months to live wouldn’t give me the time I needed to make some precious memories. I knew I would have to take the chemotherapy route to try to reduce the cancer, which in turn would hopefully reduce the calcium in my blood. In my life I’ve been blessed with a positive mind et, never been one to say, ‘what if?’ negatively. This was time to get the gloves on, time to fight!

Making that decision was so empowering. I couldn’t sit there waiting to fade away or fall prey to the debilitating chemotherapy. I understand many people have an easier journey than others on chemotherapy, but with my limited life expectancy, I needed to know my chemotherapy journey would enable me to have a quality of life to be active and enjoy my grandchildren.


Exploring medical cannabis treatments

In addition to being a decorator, I’m a complementary healthcare practitioner and I’ve had 20 years’ experience researching many potentially healing therapies. I believe that there are many avenues we can take to help in all areas of our health, and I was about to discover a great ally on my journey – medicinal cannabis. Do I hear an intake of breath, an occasional tut-tut, mutterings of illegal drugs at the mention of a natural plant that has been around for thousands of years?

To be absolutely correct, I didn’t ‘discover’ cannabis this year. I was already aware of its existence and had been for a couple of years. I was living in Portugal where the laws regarding cannabis are far more lenient than in the UK. Many people grow it for their own use and my neighbour at the time, a terminally ill lady with secondary cancer, purchased medicinal cannabis from Holland, another country that doesn’t look upon cannabis as an evil weed. I witnessed her final months and was amazed how well she managed – enjoying her life, socialising and being in her garden right up till the last two weeks of her life.

I have been in hospital a fair amount this year with the hypercalcemia and met some amazing people fighting for their lives with cancer. One lady mentioned to me she had bought some cannabis oil on the internet. At this time, I admit I didn’t have much faith in something I could ask Google for, so it was time for research.


Research, education and changing attitudes

I am blessed with a very special friend who has left no stone unturned on her quest to help me, spending hours and hours on research. That research led her first to America and then the UK – in particular to Prof Mike Barnes and The Medical Cannabis Clinics. I was told I would need to be referred by my GP to see a specialist. I can imagine the horror on some faces at the thought of approaching their GP to get cannabis!

Luckily for me,  my GP is something else. He goes that extra mile to help his patients and after his initial ‘rabbit in headlights’ reaction, he set about doing his own research and put me in touch with Dr Iveson in York.


The journey to treatment

Dr Iveson is a Consultant Physician specialising in complex care and symptom management particularly in the elderly and patients with stroke and long term conditions. She is working with the Medical Cannabis Clinician’s Society and charity Drug Science to further develop research into medical cannabis treatment and help educate and share her experience with fellow doctors.

During my initial consultation with Dr Iveson I was most impressed by her care and professionalism. My target was to take medicinal cannabis to help alleviate the potential side effects of chemotherapy such as nausea and sickness, plus help with insomnia and anxiety. I left with confidence in knowing I had made a major step forward towards a better quality of life during the daunting journey of chemotherapy.

After my initial delight in the positive attitude of my GP, I didn’t anticipate the reaction of others when I told them I was taking medicinal cannabis. Because of my research and openness to cannabis, I hadn’t realised the stigma behind something so natural. There is something about the word cannabis that really gets a reaction, either a snigger behind the hand or from friends warning me not to mention drugs in front of their partners. My favourite though is the ‘rabbit in headlights’ reaction which I received when I took my prescription to the chemist, which was followed by much huffing and puffing from the pharmacist on duty. But, the pharmacist did some research and realised he was part of something quite ground-breaking. It’s amazing what a bit of education can do!


The impact of medical cannabis treatments

I could hardly wait to begin taking my prescription. I am taking a balanced CBD:THC oil at night and a high CBD oil during the day to manage my symptoms and I am slowly titrating the dose upwards with support and close monitoring from Dr Iveson. It took a short while to appreciate all the benefits but it has been quite amazing.

My mouth ulcers have completely disappeared, I’m sleeping very well, and I’m managing my nausea and sickness so much better. One bonus I didn’t realize is that medical cannabis is an anti-inflammatory and opens the airways. It has helped my asthma and my breathing is so much better. I’m in a very positive state of mind and that in itself is a very powerful tool. My oncologist is aware I am taking medicinal cannabis and in the future perhaps we may see a great relationship forming between all health professionals working towards a better quality of life for all.


Medical cannabis for all

Medicinal cannabis is not cheap. I had some savings for a rainy day – but I didn’t think that rainy day would come so soon. My savings won’t last forever and I can only hope that in the not so distant future, the price will come down as the demand goes up. And one day, I hope it will be available to all on the NHS.


Hilary passed away in 2020. We are honoured that she chose to share her story with us.

Hannah Deacon, Executive Director, whose son, Alfie Dingley was the first patient in the UK to receive a permanent cannabis licence, tells her story.

When Alfie was born, he spent the first four months of his life in hospital, lived on and off life support and experienced his first seizure at just eight months old.

Alfie lives with a very rare form of epilepsy and, prior to medical cannabis treatment, experienced more than 500 seizures a month. Now, Alfie, aged eight, lives a relatively normal life thanks to using cannabis oil treatment.

After trying various treatments, anti-epilepsy drugs, a ketogenic diet and immuglobulins, the only treatment that reduced his seizures was a steroid called IV Methyl Prednisone that can cause severe side effects, including mood swings, restlessness and headaches.

At age five, Alfie’s condition got worse. He was visiting the hospital every week and receiving up to 25 doses of steroids a month.

Discovering medical cannabis

In 2019, Alfie’s mum Hannah, took action. After being warned by doctors around the dangers of his seizures and treatment, Hannah began to research other options for her son.

Hannah said: “When doctors advised us on the dangers of Alfie’s treatment, I needed to look into other options. I started to research epilepsy treatments and medical cannabis kept coming up – and felt confident that it was a positive option.

“I wanted to know that whatever happened, I had done everything I could to keep Alfie alive.”

After a series of setbacks from her GP, Hannah was eventually given permission to take Alfie to Holland for medical cannabis where he was assessed and immediately prescribed with the treatment he so desperately needed – Bedrolite CBD oil.


The beginning of Alfie’s miracle

After five weeks of medical cannabis treatment Alfie experienced 17 days without a seizure – the longest amount of he had ever gone without experiencing one.

Hannah said: “It was the beginning of our miracle.

“As time went by, we put up the dose of CBD and Alfie started to get better. We then added in a small amount of THC and he did even better. Treatment with cannabis oil has given Alfie a much greater quality of life and significantly reduced the number of seizures he suffers.”


Fighting for medical cannabis to be available on the NHS

Returning home, Hannah was ready to fight the biggest battle she had ever had – fighting for medical cannabis to be available on prescription for patients.

Hannah started work with the campaign group,’ End Our Pain’.  Appearing on national TV channels, she made BBC Breakfast where she told Alfie’s story.

After meeting with the Home Office but getting nowhere, Hannah submitted the group’s petition to former Prime Minister, Theresa May, and subsequently met with her.


Meeting Professor Mike Barnes

Alfie’s doctor was unfortunately unable to help due to the trust they worked for however, it was then when Hannah met Neurologist and Professor Mike Barnes. When Hannah told Mike about Alfie’s story, he agreed to help.

Hannah said: “Mike stood forward when no one else would. He gave his time and expertise for free because he felt it was the right thing to do. He has now become a lifelong friend and we now work together to improve access to medical cannabis for patients across the UK.”


Law changes for medical cannabis

In November 2018, after a long fight – the law changed which now allows medical cannabis to be prescribed as a ‘special’ by a consultant. Although around 500,000 people in the UK have epilepsy, not one more person has been prescribed the treatment on the NHS since this case.

The NHS is yet to offer medical cannabis on prescription due to very restrictive guidelines for clinicians. There is still a long way to go to ensure more people like Alfie can access medical cannabis to drastically improve the quality of their lives.